Recruiting

Galleri

Sponsor:

Weill Medical College of Cornell University

Code:

NCT07764744

Conditions

Ovarian Neoplasms

BRCA 1 Gene Mutation

BRCA 2 Gene Mutation

Serous Tubal Intraepithelial Carcinoma

Early Detection of Ovarian Cancer

Eligibility Criteria

Sex: Female

Age: 35+

Healthy Volunteers: Not accepted

Interventions

Galleri Multi-Cancer Early Detection (MCED) Blood Test

Study Details

Brief summary:

The goal of this clinical study is to evaluate the feasibility and acceptability of the Galleri multi-cancer early detection blood test in people with BRCA1 or BRCA2 gene changes who are at high risk for ovarian cancer. The study will also explore how well the test detects ovarian cancer or related precancerous conditions.

The main questions it aims to answer are:

  • Is it feasible to incorporate the Galleri blood test into the care of people at high \* risk for ovarian cancer?
  • Is the Galleri blood test acceptable to participants?
  • How well does the Galleri blood test identify ovarian cancer or related precancerous conditions?

Participants will:

  • Receive the Galleri blood test.
  • Complete questionnaires about their experience with the test.
  • Some participants will also complete an interview about their experiences and preferences.
  • Continue with their planned standard medical care, including surgery or follow-up visits, as appropriate.

Conditions

Ovarian Neoplasms

BRCA 1 Gene Mutation

BRCA 2 Gene Mutation

Serous Tubal Intraepithelial Carcinoma

Early Detection of Ovarian Cancer

Study ID

NCT07764744

Start date

Oct 7, 2026

Status verified date

Nov, 2026

Completion date

Oct, 2039

Anticipated

Primary completion date

Oct, 2039

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 35+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Cohort A participants must meet all of the following criteria:

1. Age ≥ 35 years (based on current National Comprehensive Cancer Network guidelines35 for risk-reducing gynecologic surgery) with no upper age limit
2. Confirmed germline PV or likely PV in the BRCA1 or BRCA2 genes, documented by CLIA-certified genetic testing.
3. Scheduled to undergo risk-reducing gynecologic surgery (salpingo-oophorectomy or salpingectomy with or without hysterectomy) at the study site.
4. Willing and able to provide informed consent in English This initial phase is limited to English-speaking participants. This limitation is due to feasibility considerations for initial qualitative instrument validation; future phases will incorporate translated materials

Cohort B participants must meet all of the following criteria:
5. Age ≥ 35 years with no upper age limit.
6. STIC lesion previously identified on surgical pathology within the prior 10 years.
7. Willing and able to undergo baseline and annual research blood draws for up to 10 years following STIC lesion diagnosis.
8. Willing and able to provide informed consent in English

Exclusion Criteria:

Cohort A:

1. Pregnant or breastfeeding at the time of enrollment.
2. Prior removal of bilateral fallopian tubes and/or bilateral ovaries.
3. Active diagnosis of cancer.
4. Prior or active diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer at the time of consent.
5. Patients with a history of cancer are eligible when > 2 years no evidence of disease.
6. Inability to provide informed consent.
7. Concurrent participation in another interventional trial that may confound study outcomes.

Cohort B:

1. Pregnant or breastfeeding at the time of enrollment.
2. Active diagnosis of cancer.
3. Prior or active diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer at the time of consent (prior STIC lesion is NOT a contraindication to enrollment).
4. Patients with a history of cancer are eligible when > 2 years no evidence of disease.
5. Inability to provide informed consent.
6. Concurrent participation in another interventional trial that may confound study outcomes.

Study Design

Enrollment

70 participants

Anticipated

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: Cohort A: BRCA1/2 Surgical Feasibility Cohort

Cohort A: Participants with pathogenic or likely pathogenic BRCA1/2 variants undergoing planned risk-reducing gynecologic surgery who receive the Galleri multi-cancer early detection blood test within 7 days before surgery. Liquid biopsy results will be correlated with surgical pathology findings.

experimental: Cohort B: STIC Longitudinal Surveillance Cohort

Cohort B: Participants with a prior diagnosis of serous tubal intraepithelial carcinoma (STIC) who receive the Galleri multi-cancer early detection blood test at baseline and annually for up to 10 years as part of longitudinal surveillance.

Interventions

Galleri Multi-Cancer Early Detection (MCED) Blood Test

Participants will undergo blood collection for the Galleri multi-cancer early detection (MCED) test, an investigational in vitro diagnostic device performed in a CLIA-certified laboratory. Results will be evaluated for feasibility, acceptability, and exploratory diagnostic performance for early detection of epithelial ovarian cancer in high-risk individuals.

Primary outcome measure

  • Feasibility of Galleri testing in BRCA1/2 surgical cohort A [ Time Frame: Within 7 days before surgery ]
  • Feasibility of annual Galleri testing in STIC cohort B [ Time Frame: Up to 10 years ]

Central Contacts and Locations

Central contacts

Melissa K Frey, Study Official, MD, MS

646-697-6621mkf2002@med.cornell.edu

Locations

Weill Cornell Medicine

Recruiting

New York, New York, United States, 10065

Contacts

Principal Investigator:

Melissa K Frey, MD, MS

More Information

Sponsor

Weill Medical College of Cornell University

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Keywords

  • Ovarian cancer
  • Liquid biopsy
  • Galleri
  • Multi-cancer early detection
  • BRCA1
  • BRCA2
  • Hereditary breast and ovarian cancer syndrome
  • Serous tubal intraepithelial carcinoma (STIC)
  • Risk-reducing salpingo-oophorectomy
  • Early cancer detection
  • Hereditary cancer
  • Cancer screening
  • Implementation science

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Weill Medical College of Cornell University on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.